The Impact of FEV1/FVC Ratio on the Clinical Outcomes in Acute Coronary Syndrome Patients Treated with Dual Anti-Platelet Agents

Overview

Journal Acta Cardiol Sin

Date 2023 Jan 23

PMID 36685154

Authors

Chia-Hung Yeh

Wen-Jung Chung

Tien-Yu Chen

Po-Jui Wu

Chien-Hao Tseng

Chien-Ho Lee

Cheng-I Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have investigated the clinical efficacy and pulmonary side effects of different P2Y12 inhibitors in acute coronary syndrome (ACS) patients. The aim of this study was to explore the impact of forced expiratory volume in 1 second over forced vital capacity (FEV1/FVC) ratio on the clinical outcomes in ACS patients treated with dual antiplatelet therapy after percutaneous coronary intervention (PCI).

Methods: ACS patients who underwent PCI, had documented pre-existing spirometry tests, and received aspirin with either ticagrelor or clopidogrel were enrolled for retrospective analysis.

Results: Of the enrolled ACS patients, 275 and 247 received ticagrelor and clopidogrel, respectively. The incidence of wheeze was significantly higher in the ticagrelor group compared to the clopidogrel group within 360 days (14.91% vs. 8.09%, p = 0.016). Multivariable analysis revealed that ticagrelor treatment, as compared to clopidogrel treatment, independently predicted 1-year hospitalization for acute exacerbation (AE) of obstructive airway disease (hazard ratio: 3.44; 95% confidence interval: 1.92 to 6.15; p < 0.01). The receiver operating characteristic curve indicated that an FEV1/FVC ratio of 63.85% had the highest sensitivity and specificity for predicting the incidence of AE of obstructive airway disease within 1 year (p < 0.001). The 1-year hospitalization rate for AE of obstructive airway disease was significantly higher in the ticagrelor group when the FEV1/FVC ratio was < 63%.

Conclusions: This study demonstrated higher incidence of wheeze and hospitalization for AE of obstructive airway disease in ACS patients treated with ticagrelor compared to clopidogrel. Furthermore, the FEV1/FVC ratio ≤ 63% in the ACS patients predicted hospitalization for AE of obstructive airway disease in 1 year.

Citing Articles

Should Ticagrelor Be Used with Caution in Patients with Low FEV1/FVC?.

Oncel C, Koseoglu C Acta Cardiol Sin. 2023; 39(6):945.

PMID: 38022418 PMC: 10646585. DOI: 10.6515/ACS.202311_39(6).20230529A.

References

Leitao Filho F, Alotaibi N, Yamasaki K, Ngan D, Sin D . The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2017; 12(2):125-135. DOI: 10.1080/17476348.2018.1419869. View

Kunadian V, Chan D, Ali H, Wilkinson N, Howe N, McColl E . Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2). BMJ Open. 2018; 8(5):e020713. PMC: 5988059. DOI: 10.1136/bmjopen-2017-020713. View

Su T, Chang S, Kuo C, Liu P, Chan Y . β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS One. 2019; 14(3):e0213187. PMC: 6400336. DOI: 10.1371/journal.pone.0213187. View

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

Parshall M, Schwartzstein R, Adams L, Banzett R, Manning H, Bourbeau J . An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185(4):435-52. PMC: 5448624. DOI: 10.1164/rccm.201111-2042ST. View

Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016; 133(4):447-54. DOI: 10.1161/CIR.0000000000000366. View

Gaubert M, Laine M, Richard T, Fournier N, Gramond C, Bessereau J . Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014; 173(1):120-1. DOI: 10.1016/j.ijcard.2014.02.028. View

Bohadana A, Izbicki G, Kraman S . Fundamentals of lung auscultation. N Engl J Med. 2014; 370(8):744-51. DOI: 10.1056/NEJMra1302901. View

Gurbel P, Bliden K, Butler K, Tantry U, Gesheff T, Wei C . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25):2577-85. DOI: 10.1161/CIRCULATIONAHA.109.912550. View

10.

Suissa S, DellAniello S, Ernst P . Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017; 49(5). DOI: 10.1183/13993003.02245-2016. View

11.

Orme R, Parker W, Thomas M, Judge H, Baster K, Sumaya W . Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Circulation. 2018; 138(13):1290-1300. PMC: 6159686. DOI: 10.1161/CIRCULATIONAHA.118.034790. View

12.

Su T, Chang S, Chen P, Chan Y . Temporal Trends in Treatment and Outcomes of Acute Myocardial Infarction in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Observational Study. J Am Heart Assoc. 2017; 6(3). PMC: 5524002. DOI: 10.1161/JAHA.116.004525. View

13.

Abergel E, Nikolsky E . Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag. 2010; 6:963-77. PMC: 2964949. DOI: 10.2147/VHRM.S13263. View

14.

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S . A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021; 16:1461-1475. PMC: 8180309. DOI: 10.2147/COPD.S301624. View

15.

Almagro P, Lapuente A, Pareja J, Yun S, Garcia M, Padilla F . Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis. 2015; 10:1353-61. PMC: 4509531. DOI: 10.2147/COPD.S84482. View

16.

Parodi G, Storey R . Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2014; 4(6):555-60. PMC: 4657388. DOI: 10.1177/2048872614554108. View

17.

Storey R, Bliden K, Ecob R, Karunakaran A, Butler K, Wei C . Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost. 2011; 9(9):1730-7. DOI: 10.1111/j.1538-7836.2011.04419.x. View

18.

James S, Akerblom A, Cannon C, Emanuelsson H, Husted S, Katus H . Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009; 157(4):599-605. DOI: 10.1016/j.ahj.2009.01.003. View

19.

Akerblom A, Wojdyla D, Wallentin L, James S, Brito F, Steg P . Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2019; 213:57-65. DOI: 10.1016/j.ahj.2019.04.006. View

20.

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68(10):1082-115. DOI: 10.1016/j.jacc.2016.03.513. View